From Yahoo Finance: 2025-06-17 13:32:00

UroGen Pharma Ltd. (NASDAQ:URGN) is one of the best NASDAQ stocks under $50 to buy. Analysts at H.C. Wainwright raised the rating to Buy with a price target of $50.00 after regulatory approval of Zusduri at $21,500 per dose.

With a stock price increase of over 100% in the past five days, UroGen Pharma Ltd. (NASDAQ:URGN) has an impressive gross margin of around 90%. The company is set to launch a product for non-muscle invasive bladder cancer, with potential sales reaching $1 billion by 2026.

UroGen Pharma Ltd. (NASDAQ:URGN) is a clinical-stage biopharmaceutical company founded in 2004. Based in New Jersey, the company focuses on developing and marketing treatments for urothelial and specialty cancers.

Analysts are seeking clarity on the approval path for UGN-103, but UroGen Pharma Ltd. (NASDAQ:URGN) management believes potential changes to the clinical trial strategy will not significantly impact financial outlook. UGN-103 is crucial for extending the company’s franchise exclusivity beyond early 2031.

Read more: H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy